Intranasal COVID-19 vaccine candidate shows sterilizing immunity in preclinical tests
University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate—AdCOVID—that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.
